This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Health Policy  • Law and Medicine  • Statistics and Research Methods  • Alert me on articles by topic

Tracy Hampton, PhD

JAMA. 2006;295:2233-2234.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The current climate for stem cell researchers in the United States is decidedly mixed. Just days after the publication of a report last month documenting that the United States is falling behind other countries in publishing human embryonic stem cell studies, the California Institute for Regenerative Medicine (CIRM) awarded its first grants for stem cell research. This event follows the passage of the California Stem Cell Research and Cures Initiative (Proposition 71), which allows CIRM to distribute state funds for stem cell research in California. In addition to California, some states are committing funds to human stem cell research to counteract restrictive federal policies, but others have additional limits or even complete bans on research that uses human embryos.

"Right now, I think the environment for research in the US is challenging because funding is uncertain and complicated, there's much pressure for quick therapeutic payoffs, and the . . . [Full Text of this Article]

FALLING BEHIND